Kynurenines, neurodegeneration and Alzheimer's disease

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 8, 2010, Pages 2045-2054

  Kincses, Zsigmond Tamas ^a   Toldi, József ^b   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Alzheimer; Glutamate excitotoxicity; Kynurenine; Neuroinflammation; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; KYNURENINE; QUINOLINIC ACID; TRYPTOPHAN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; NERVE DEGENERATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOSYNTHETIC PATHWAYS; HUMANS; KYNURENINE; MOLECULAR STRUCTURE; NERVE DEGENERATION; PLAQUE, AMYLOID; QUINOLINIC ACID; TRYPTOPHAN;

EID: 77957131120     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01123.x     Document Type: Article

References (150)

1. Dartigues JF. Alzheimer's disease: a global challenge for the 21st century. Lancet Neurol 2009, 8:1082-3.
2. Ferri CP, Sousa R, Albanese E. World Alzheimer report 2009. Alzheimer Disease International 2009, 1-93. Prince M, Jackson J, editors, London, p
3. Keri S, Kalman J, Kelemen O. Are Alzheimer's disease patients able to learn visual prototypes. Neuropsychologia 2001, 39:1218-23.
4. Antal A, Keri S, Kincses T. Corticostriatal circuitry mediates fast-track visual categorization. Brain Res Cogn Brain Res 2002, 13:53-9.
5. Hoffmann I, Nemeth D, Dye CD. Temporal parameters of spontaneous speech in Alzheimer's disease. Int J Speech Lang Pathol 2010, 12:29-34.
6. Waltz JA, Knowlton BJ, Holyoak KJ. Relational integration and executive function in Alzheimer's disease. Neuropsychology 2004, 18:296-305.
7. Salmon DP, Butters N, Chan AS. The deterioration of semantic memory in Alzheimer's disease. Can J Exp Psychol 1999, 53:108-17.
8. Filippini N, Rao A, Wetten S. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease. Neuroimage 2009, 44:724-8.
9. Zarei M, Patenaude B, Damoiseaux J. Combining shape and connectivity analysis: an MRI study of thalamic degeneration in Alzheimer's disease. Neuroimage 2010, 49:1-8.
10. Zarei M, Damoiseaux JS, Morgese C. Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. Stroke 2009, 40:773-9.
11. Smith SM, Rao A, De Stefano N. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage 2007, 36:1200-6.
12. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-5.
13. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120:885-90.
14. Masters CL, Simms G, Weinman NA. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82:4245-9.
15. Kang J, Lemaire HG, Unterbeck A. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-6.
16. Goldgaber D, Lerman MI, McBride OW. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987, 235:877-80.
17. Tanzi RE, Gusella JF, Watkins PC. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235:880-4.
18. Robakis NK, Ramakrishna N, Wolfe G. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci USA 1987, 84:4190-4.
19. Scheuner D, Eckman C, Jensen M. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2:864-70.
20. Goate A, Chartier-Harlin MC, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-6.
21. Mullan M, Crawford F, Axelman K. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1:345-7.
22. Hardy J. Framing beta-amyloid. Nat Genet 1992, 1:233-4.
23. Hendriks L, van Duijn CM, Cras P. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992, 1:218-21.
24. Haass C, Hung AY, Selkoe DJ. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem 1994, 269:17741-8.
25. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009, 110:1129-34.
26. Vamos E, Pardutz A, Klivenyi P. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci 2009, 283:21-7.
27. Zadori D, Klivenyi P, Vamos E. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 2009, 116:1403-9.
28. Sas K, Robotka H, Toldi J. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007, 257:221-39.
29. Kessler M, Terramani T, Lynch G. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989, 52:1319-28.
30. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 1988, 154:85-7.
31. Birch PJ, Grossman CJ, Hayes AG. Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 1988, 151:313-5.
32. Hilmas C, Pereira EF, Alkondon M. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21:7463-73.
33. Rozsa E, Robotka H, Vecsei L. The Janus-face kynurenic acid. J Neural Transm 2008, 115:1087-91.
34. Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-8.
35. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 1981, 72:411-2.
36. Tavares RG, Tasca CI, Santos CE. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002, 40:621-7.
37. Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991, 16:1139-43.
38. Santamaria A, Galvan-Arzate S, Lisy V. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 2001, 12:871-4.
39. Eastman CL, Guilarte TR. Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res 1989, 495:225-31.
40. Nakagami Y, Saito H, Katsuki H. 3-Hydroxykynurenine toxicity on the rat striatum in vivo. Jpn J Pharmacol 1996, 71:183-6.
41. Eastman CL, Guilarte TR. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 1990, 15:1101-7.
42. Okuda S, Nishiyama N, Saito H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 1998, 70:299-307.
43. Guillemin GJ, Kerr SJ, Smythe GA. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001, 78:842-53.
44. Guillemin GJ, Brew BJ, Noonan CE. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005, 31:395-404.
45. Han Q, Cai T, Tagle DA. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci 2010, 67:353-68.
46. Guidetti P, Amori L, Sapko MT. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem 2007, 102:103-11.
47. Han Q, Li J. pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I. Eur J Biochem 2004, 271:4804-14.
48. Han Q, Robinson H, Cai T. Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K. J Med Chem 2009, 52:2786-93.
49. Guidetti P, Hoffman GE, Melendez-Ferro M. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 2007, 55:78-92.
50. Roberts RC, Du F, McCarthy KE. Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. J Comp Neurol 1992, 326:82-90.
51. Cechetto JD, Sadacharan SK, Berk PD. Immunogold localization of mitochondrial aspartate aminotransferase in mitochondria and on the cell surface in normal rat tissues. Histol Histopathol 2002, 17:353-64.
52. Lehrmann E, Molinari A, Speciale C. Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum. Exp Brain Res 2001, 141:389-97.
53. Kohler C, Eriksson LG, Flood PR. Quinolinic acid metabolism in the rat brain. Immunohistochemical identification of 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyltransferase in the hippocampal region. J Neurosci 1988, 8:975-87.
54. Roberts RC, McCarthy KE, Du F. 3-Hydroxyanthranilic acid oxygenase-containing astrocytic processes surround glutamate-containing axon terminals in the rat striatum. J Neurosci 1995, 15:1150-61.
55. Guillemin GJ, Kerr SJ, Smythe GA. Kynurenine pathway metabolism in human astrocytes. Adv Exp Med Biol 1999, 467:125-31.
56. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res 2005, 2:249-60.
57. Vecsei L, Schwab F. Kynurenine and its metabolites in nervous system diseases. Orv Hetil 1992, 133:1803-7.
58. Vecsei L, Beal MF. Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives. Biol Psychiatry 1996, 39:1061-3.
59. Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl 2006, 285-304.
60. Hartai Z, Klivenyi P, Janaky T. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci 2005, 239:31-5.
61. Rakoczi K, Klivenyi P, Vecsei L. Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings. Ideggyogy Sz 2009, 62:25-34.
62. Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. CNS Neurosci Ther 2010, 10.1111/j.1755-5949.2010.00150.x, DOI
63. Hartai Z, Klivenyi P, Janaky T. Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand 2005, 112:93-6.
64. Rajda C, Bergquist J, Vecsei L. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. J Neural Transm Suppl 2007, 72:323-9.
65. Hartai Z, Klivenyi P, Janaky T. Peripheral kynurenine metabolism in focal dystonia. Med Chem 2007, 3:285-8.
66. Knyihar-Csillik E, Chadaide Z, Okuno E. Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion. Exp Neurol 2004, 186:242-7.
67. Knyihar-Csillik E, Toldi J, Mihaly A. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J Neural Transm 2007, 114:417-21.
68. Vamos E, Pardutz A, Varga H. l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 2009, 57:425-9.
69. Knyihar-Csillik E, Toldi J, Krisztin-Peva B. Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci Lett 2007, 418:122-6.
70. Widner B, Leblhuber F, Walli J. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000, 107:343-53.
71. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999, 106:165-81.
72. Tapiola T, Lehtovirta M, Pirttila T. Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease. Lancet 1998, 352:287.
73. Hartai Z, Juhasz A, Rimanoczy A. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 2007, 50:308-13.
74. Heyes MP, Saito K, Crowley JS. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115:1249-73.
75. Sofic E, Halket J, Przyborowska A. Brain quinolinic acid in Alzheimer's dementia. Eur Arch Psychiatry Neurol Sci 1989, 239:177-9.
76. Guillemin GJ, Williams KR, Smith DG. Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol 2003, 527:167-76.
77. Guillemin GJ, Smythe GA, Veas LA. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 2003, 14:2311-5.
78. Hirai K, Aliev G, Nunomura A. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001, 21:3017-23.
79. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 2006, 96:1-13.
80. Zhu X, Lee HG, Casadesus G. Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 2005, 31:205-17.
81. Hensley K, Carney JM, Mattson MP. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:3270-4.
82. Leutner S, Czech C, Schindowski K. Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci Lett 2000, 292:87-90.
83. Sayre LM, Zelasko DA, Harris PL. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997, 68:2092-7.
84. Good PF, Werner P, Hsu A. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996, 149:21-8.
85. McLellan ME, Kajdasz ST, Hyman BT. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 2003, 23:2212-7.
86. Yamaguchi H, Yamazaki T, Ishiguro K. Ultrastructural localization of Alzheimer amyloid beta/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes. Acta Neuropathol 1992, 85:15-22.
87. Manczak M, Anekonda TS, Henson E. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006, 15:1437-49.
88. Lustbader JW, Cirilli M, Lin C. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-52.
89. Crouch PJ, Barnham KJ, Duce JA. Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. J Neurochem 2006, 99:226-36.
90. Devi L, Prabhu BM, Galati DF. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 2006, 26:9057-68.
91. Sirk D, Zhu Z, Wadia JS. Chronic exposure to sub-lethal beta-amyloid (Abeta) inhibits the import of nuclear-encoded proteins to mitochondria in differentiated PC12 cells. J Neurochem 2007, 103:1989-2003.
92. Moreira PI, Santos MS, Moreno A. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep 2001, 21:789-800.
93. Du H, Guo L, Fang F. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 2008, 14:1097-105.
94. Hussain I, Powell D, Howlett DR. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999, 14:419-27.
95. Hussain I, Powell DJ, Howlett DR. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci 2000, 16:609-19.
96. Tamagno E, Bardini P, Obbili A. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002, 10:279-88.
97. Santamaria A, Rios C. MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci Lett 1993, 159:51-4.
98. Stipek S, Stastny F, Platenik J. The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem Int 1997, 30:233-7.
99. Rodriguez-Martinez E, Camacho A, Maldonado PD. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res 2000, 858:436-9.
100. Santamaria D, Espinoza-Gonzalez V, Rios C. Nomega-nitro-L-arginine, a nitric oxide synthase inhibitor, antagonizes quinolinic acid-induced neurotoxicity and oxidative stress in rat striatal slices. Neurochem Res 1999, 24:843-8.
101. Luchowski P, Kocki T, Urbanska EM. N(G)-nitro-L-arginine and its methyl ester inhibit brain synthesis of kynurenic acid possibly via nitric oxide-independent mechanism. Pol J Pharmacol 2001, 53:597-604.
102. Rozsa E, Robotka H, Nagy D. The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of L-kynurenine to kynurenic acid: an in vitro study. Brain Res Bull 2008, 76:474-9.
103. Nakai M, Qin ZH, Wang Y. Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum. Brain Res Mol Brain Res 1999, 64:59-68.
104. Nakao N, Brundin P. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience 1997, 76:749-61.
105. Choi DW. Excitotoxic cell death. J Neurobiol 1992, 23:1261-76.
106. Koh JY, Choi DW. Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death. Brain Res 1991, 548:318-21.
107. Siman R, Noszek JC. Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron 1988, 1:279-87.
108. Lazarewicz JW, Wroblewski JT, Costa E. N-methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells. J Neurochem 1990, 55:1875-81.
109. Chen KC, Chang LS. Arachidonic acid-induced apoptosis of human neuroblastoma SK-N-SH cells is mediated through mitochondrial alteration elicited by ROS and Ca(2+)-evoked activation of p38alpha MAPK and JNK1. Toxicology 2009, 262:199-206.
110. Chan SF, Sucher NJ. An NMDA receptor signaling complex with protein phosphatase 2A. J Neurosci 2001, 21:7985-92.
111. Rahman A, Ting K, Cullen KM. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 2009, 4:e6344.
112. Braidy N, Grant R, Adams S. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 2009, 16:77-86.
113. Li L, Sengupta A, Haque N. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004, 566:261-9.
114. Tavares RG, Schmidt AP, Abud J. In vivo quinolinic acid increases synaptosomal glutamate release in rats: reversal by guanosine. Neurochem Res 2005, 30:439-44.
115. Kumar A, Babu GN. In vivo neuroprotective effects of peripheral kynurenine on acute neurotoxicity induced by glutamate in rat cerebral cortex. Neurochem Res 2010, 35:636-44.
116. Styren SD, Civin WH, Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol 1990, 110:93-104.
117. McGeer PL, Itagaki S, Tago H. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987, 79:195-200.
118. Mackenzie IR, Hao C, Munoz DG. Role of microglia in senile plaque formation. Neurobiol Aging 1995, 16:797-804.
119. Mizoguchi A, Arakawa M, Masutani M. Localization of smg p25A/rab3A p25, a small GTP-binding protein, at the active zone of the rat neuromuscular junction. Biochem Biophys Res Commun 1992, 186:1345-52.
120. Wisniewski HM, Wegiel J, Wang KC. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol 1992, 84:117-27.
121. Cagnin A, Brooks DJ, Kennedy AM. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-7.
122. Edison P, Archer HA, Gerhard A. Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008, 32:412-9.
123. D'Andrea MR, Cole GM, Ard MD. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging 2004, 25:675-83.
124. Akiyama H, Barger S, Barnum S. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
125. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-32.
126. Combs CK. Inflammation and microglia actions in Alzheimer's disease. J Neuroimmune Pharmacol 2009, 4:380-8.
127. Heyes MP, Saito K, Major EO. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993, 116:1425-50.
128. Naritsin DB, Saito K, Markey SP. Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. J Neurochem 1995, 65:2217-26.
129. Heyes MP, Achim CL, Wiley CA. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 1996, 320:595-7.
130. Espey MG, Chernyshev ON, Reinhard JF. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 1997, 8:431-4.
131. Guillemin GJ, Smith DG, Smythe GA. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 2003, 527:105-12.
132. Walker DG, Link J, Lue LF. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006, 79:596-610.
133. Gan L, Ye S, Chu A. Identification of cathepsin B as a mediator of neuronal death induced by Abeta-activated microglial cells using a functional genomics approach. J Biol Chem 2004, 279:5565-72.
134. Yamada A, Akimoto H, Kagawa S. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J Neurochem 2009, 110:791-800.
135. Guillemin GJ, Smythe G, Takikawa O. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49:15-23.
136. Ting KK, Brew BJ, Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation 2009, 6:36-49.
137. Dihne M, Block F, Korr H. Time course of glial proliferation and glial apoptosis following excitotoxic CNS injury. Brain Res 2001, 902:178-89.
138. Hanbury R, Charles V, Chen EY. Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors. J Comp Neurol 2002, 444:291-305.
139. Guillemin GJ, Croitoru-Lamoury J, Dormont D. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 2003, 41:371-81.
140. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004, 4:12-7.
141. Fukui S, Schwarcz R, Rapoport SI. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991, 56:2007-17.
142. Wu HQ, Lee SC, Scharfman HE. L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat. Exp Neurol 2002, 177:222-32.
143. Guidetti P, Wu HQ, Schwarcz R. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum. Exp Neurol 2000, 163:123-30.
144. Wu HQ, Salituro FG, Schwarcz R. Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo. Eur J Pharmacol 1997, 319:13-20.
145. Fulop F, Szatmari I, Vamos E. Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 2009, 16:4828-42.
146. Marosi M, Nagy D, Farkas T. A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study. J Neural Transm 2010, 117:183-8.
147. Miranda AF, Boegman RJ, Beninger RJ. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 1997, 78:967-75.
148. Harris CA, Miranda AF, Tanguay JJ. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol 1998, 124:391-9.
149. Giorgini F, Guidetti P, Nguyen Q. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005, 37:526-31.
150. Amori L, Guidetti P, Pellicciari R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem 2009, 109:316-25.